Logo image of ERNA

ETERNA THERAPEUTICS INC (ERNA) Stock Fundamental Analysis

NASDAQ:ERNA - Nasdaq - US1140822099 - Common Stock - Currency: USD

0.3389  -0.01 (-3.61%)

Premarket: 0.341 +0 (+0.62%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ERNA. ERNA was compared to 571 industry peers in the Biotechnology industry. Both the profitability and financial health of ERNA have multiple concerns. ERNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ERNA has reported negative net income.
In the past year ERNA has reported a negative cash flow from operations.
In the past 5 years ERNA always reported negative net income.
In the past 5 years ERNA reported 4 times negative operating cash flow.
ERNA Yearly Net Income VS EBIT VS OCF VS FCFERNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -582.39%, ERNA is not doing good in the industry: 98.22% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -582.39%
ROE N/A
ROIC N/A
ROA(3y)-181.08%
ROA(5y)-135.19%
ROE(3y)-551.61%
ROE(5y)-443.3%
ROIC(3y)N/A
ROIC(5y)N/A
ERNA Yearly ROA, ROE, ROICERNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

1.3 Margins

ERNA has a Gross Margin of 72.91%. This is amongst the best in the industry. ERNA outperforms 84.37% of its industry peers.
The Profit Margin and Operating Margin are not available for ERNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ERNA Yearly Profit, Operating, Gross MarginsERNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

ERNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ERNA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ERNA has been increased compared to 5 years ago.
ERNA has a worse debt/assets ratio than last year.
ERNA Yearly Shares OutstandingERNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
ERNA Yearly Total Debt VS Total AssetsERNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -50.18, we must say that ERNA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -50.18, ERNA is not doing good in the industry: 94.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -50.18
ROIC/WACCN/A
WACC8.29%
ERNA Yearly LT Debt VS Equity VS FCFERNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

ERNA has a Current Ratio of 0.48. This is a bad value and indicates that ERNA is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.48, ERNA is doing worse than 93.61% of the companies in the same industry.
ERNA has a Quick Ratio of 0.48. This is a bad value and indicates that ERNA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.48, ERNA is not doing good in the industry: 93.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.48
Quick Ratio 0.48
ERNA Yearly Current Assets VS Current LiabilitesERNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ERNA have decreased strongly by -98.75% in the last year.
The Revenue has grown by 1096.00% in the past year. This is a very strong growth!
Measured over the past years, ERNA shows a very negative growth in Revenue. The Revenue has been decreasing by -68.89% on average per year.
EPS 1Y (TTM)-98.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-377.43%
Revenue 1Y (TTM)1096%
Revenue growth 3Y-77.28%
Revenue growth 5Y-68.89%
Sales Q2Q%874%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ERNA Yearly Revenue VS EstimatesERNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ERNA Yearly EPS VS EstimatesERNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ERNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERNA Price Earnings VS Forward Price EarningsERNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ERNA Per share dataERNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ERNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ETERNA THERAPEUTICS INC

NASDAQ:ERNA (2/20/2025, 8:13:42 PM)

Premarket: 0.341 +0 (+0.62%)

0.3389

-0.01 (-3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-11 2024-11-11/amc
Earnings (Next)03-12 2025-03-12
Inst Owners7.21%
Inst Owner Change39.8%
Ins Owners8.45%
Ins Owner Change0%
Market Cap17.41M
Analysts43.33
Price TargetN/A
Short Float %1.09%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-60.39%
DP-0.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.11
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-8.31
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.01
BVpS-0.88
TBVpS-0.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -582.39%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.91%
FCFM N/A
ROA(3y)-181.08%
ROA(5y)-135.19%
ROE(3y)-551.61%
ROE(5y)-443.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 269.44%
Cap/Sales 64.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.48
Quick Ratio 0.48
Altman-Z -50.18
F-Score3
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)111.71%
Cap/Depr(5y)77.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-98.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-377.43%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1096%
Revenue growth 3Y-77.28%
Revenue growth 5Y-68.89%
Sales Q2Q%874%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.23%
OCF growth 3YN/A
OCF growth 5YN/A